CEO Wayne Paterson is interviewed by Ausbiz

The $5 billion market for valves to treat aortic stenosis, the most common heart valve disease, has the potential to double by 2025. CEO of Anteris Technologies, Wayne Paterson, was live with us and says the key points of difference for the Anteris valve are the anti-calcification feature and unique design. This innovation avoids the need for open-heart surgery, reducing the amount of time it requires for a patient to recover.

TAVR Key Opinion Leader Symposium

Full Video & CEO Presentation Deck

Bioshares July 2020 Report

Anteris Technologies TAVR Advisory Board Signals High Level Interest

Anteris Technologies delivering on its goals despite pandemic

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are underway and says he's extremely thrilled with the results to date from its first-in-human study. Paterson's expecting the company will end the year achieving all milestones set for 2020.

ShareCafe's Hidden Gems Webinar – Anteris (AVR)

Latest video outlining Anteris direction to build the World's Most Durable Heart Valve

StockPal Interview with Wayne Paterson

Anteris Technologies (ASX:AVR) – Wayne Paterson

Bioshares - Admedus Name Change

Admedus has changed its name to Anteris Technologies

Company Name Change

Change of company name from Admedus to Anteris Technologies

Admedus 2020 AGM

Admedus 2020 AGM Video

CEO Wayne Paterson is interviewed by Proactive Investors

CEO Wayne Paterson is interviewed by proactive investors to provide an update on Admedus in light of COVID-19

First patient implanted with DurAVR™

Admedus implants first patient with their 3D single piece aortic valve

Investor Q&A with Dr. Paul Sorajja & our CEO

Dr. Paul Sorajja shares his view on Admedus' TAVR